Sugi Predict

Sugi Predict / Compounds / SCHEMBL396064

SCHEMBL396064

SCHEMBL396064

N#Cc1ccc(Br)cc1C(Br)Br

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ MAOB P27338 4/20 0.44
▸ MAOA P21397 3/20 0.44
▸ MCL1 Q07820 1/20 0.37
▸ NOS3 P29474 1/20 0.35
▸ NOS1 P29475 1/20 0.35
▸ NOS2 P35228 1/20 0.35
▸ CYP11B1 P15538 1/20 0.34
▸ CYP11B2 P19099 1/20 0.34
▸ CHEK1 O14757 1/20 0.34
▸ CYP2A6 P11509 1/20 0.33
▸ AHR P35869 1/20 0.33
▸ NR4A2 P43354 1/20 0.33
▸ SLC1A5 Q15758 1/20 0.33
▸ IDH1 O75874 1/20 0.33
▸ CSNK2A1 P68400 2/20 0.33
▸ LMNA P02545 1/20 0.33
▸ TRPV4 Q9HBA0 2/20 0.32
▸ SMN1; SMN2 Q16637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24416900 0.85 MAOB (0.39) MAOBMAOAMCL1NOS3NOS1
SCHEMBL16897459 0.83 MAOB (0.42) MAOBMAOAMCL1NOS3NOS1
SCHEMBL13571070 0.81 GABRA1 (0.43) MAOBMAOAMCL1NOS3NOS1
SCHEMBL16033846 0.81 MAOB (0.43) MAOBMAOAMCL1NOS3NOS1
SCHEMBL4632656 0.81 IMPDH2 (0.41) MAOBMAOANOS3NOS1NOS2
SCHEMBL14259302 0.79 AR (0.39) MAOBMAOAMCL1CYP2A6SMN1; SMN2
SCHEMBL584461 0.79 VCAM1 (0.44) MAOBMAOAMCL1NOS3NOS1
SCHEMBL28452472 0.79 TRPV4 (0.42) MAOBMAOACYP11B1CYP11B2TRPV4
SCHEMBL16958325 0.78 MAOB (0.41) MAOBMAOAMCL1NOS3NOS1
SCHEMBL16956877 0.78 MAOB (0.41) MAOBMAOAMCL1NOS3NOS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4051680-B1 CONDENSED BI-HETEROCYCLES AS INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE BIOGEN MA INC (US) 2025-09-03 — — EP disclosed
US-12391697-B2 Condensed bi-heterocycles as inhibiting agents for Bruton's tyrosine kinase BIOGEN MA INC. (US) 2025-08-19 — — US disclosed
US-20250122173-A1 MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE REDX PHARMA LTD (GB) 2025-04-17 — — US disclosed
EP-4466071-A1 MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE (ROCK) Redx Pharma Limited (GB) 2024-11-27 — — EP disclosed
US-20240327380-A1 BTK INHIBITORS BIOGEN MA INC. (US) 2024-10-03 — — US disclosed
CN-118632845-A Modulators of Rho-associated protein kinase (ROCK) 莱德克斯制药有限公司 2024-09-10 — — CN disclosed
CN-116917279-A BTK inhibitors 渤健马萨诸塞州股份有限公司 2023-10-20 — — CN disclosed
WO-2023139379-A1 MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE (ROCK) REDX PHARMA PLC (GB) 2023-07-27 — — WO disclosed
WO-2023139379-A1 MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE (ROCK) REDX PHARMA PLC (GB) 2023-07-27 — — WO disclosed
EP-4192587-A1 BTK INHIBITORS Biogen MA Inc. (US) 2023-06-14 — — EP disclosed
WO-2006094187-A2 PHTHALAZINE, AZA- AND DIAZA-PHTHALAZINE COMPOUNDS AND METHODS OF USE AMGEN INC (US) 2006-09-08 — — WO disclosed
US-20060199817-A1 Phthalazine, aza- and diaza-phthalazine compounds and methods of use AMGEN INC. (US) 2006-09-07 — — US disclosed
US-20060173003-A1 Substituted quinazolin-4-ylamine analogues NEUROGEN CORPORATION (US) 2006-08-03 — — US disclosed
US-7074799-B2 Substituted quinazolin-4-ylamine analogues NEUROGEN CORPORATION (US) 2006-07-11 — — US disclosed
EP-1581225-A1 COMBINATION THERAPY FOR THE TREATMENT OF PAIN NEUROGEN CORPORATION (US) 2005-10-05 — — EP disclosed
EP-1471910-A2 SUBSTITUTED QUINAZOLIN-4-YLAMINE ANALOGUES AS MODULATORS OF CAPSAICIN RECEPTORS NEUROGEN CORPORATION (US) 2004-11-03 — — EP disclosed
US-20040142958-A1 Combination therapy for the treatment of pain NEUROGEN CORPORATION 2004-07-22 — — US disclosed
WO-2004054582-A1 COMBINATION THERAPY FOR THE TREATMENT OF PAIN NEUROGEN CORPORATION (US) 2004-07-01 — — WO disclosed
US-20040106616-A1 Substituted quinazolin-4-ylamine analogues NEUROGEN CORPORATION 2004-06-03 — — US disclosed
WO-2003062209-A2 SUBSTITUTED QUINAZOLIN-4-YLAMINE ANALOGUES AS MODULATORS OF CAPSAICIN NEUROGEN CORPORATION (US) 2003-07-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060199817-A1 Phthalazine, aza- and diaza-phthalazine compounds and methods of use DAPK2, CDK2, DAPK1 MAOB 2100/4885MAOA 1527/4885MCL1 1410/4885
US-20240327380-A1 BTK INHIBITORS BTK, SYK, LYN MAOB 1936/4885MAOA 2809/4885MCL1 354/4885
US-20040142958-A1 Combination therapy for the treatment of pain OPRK1, OPRL1, OPRM1 MAOB 1283/4885MAOA 1452/4885MCL1 2138/4885
US-20250122173-A1 MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE ROCK1, ROCK2, RHOA MAOB 2161/4885MAOA 2052/4885MCL1 1905/4885
US-12391697-B2 Condensed bi-heterocycles as inhibiting agents for Bruton's tyrosine kinase ABL1, CDK1, CDK2 MAOB 379/4885MAOA 1048/4885MCL1 112/4885
US-20060173003-A1 Substituted quinazolin-4-ylamine analogues PIGS, HRH4, GPR88 MAOB 1527/4885MAOA 1075/4885MCL1 3929/4885
US-20040106616-A1 Substituted quinazolin-4-ylamine analogues PIGS, HRH4, GPR88 MAOB 1680/4885MAOA 1139/4885MCL1 3713/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.